BM4SIT is a health project supported by the European Union
Latest News
  • This page is not being updated since 11th August, 2020. For updates and latest news please visit this site.

Translational Focus of BM4SIT

The BM4SIT project funded, by the European Union within the 7th Framework program under the call identifier FP7-HEALTH-2013-INNOVATION-1, is a strongly product- and patient-focused initiative. Therefore, the consortium composed of 7 partner organizations, a small industrial partner (SME) preparing the innovative vaccine, and 4 clinical centers in four countries, evaluating the vaccine in clinical trials, plays a key role in the project. 

Research & Innovation

Within the consortium 4 clinical research centers of excellence with long-standing experience in performing and coordinating multi-centered randomized controlled clinical trials are entrusted with the clinical part of the project.

BM4SIT is supported by academic partners with outstanding expertise in molecular biology, proteomics, protein chemistry and immunochemistry of allergenic molecules and derivatives. Immunoassay development, quality control of the drug substance and drug product for BM4SIT, and the control of serological and cellular immune responses during the clinical trials will be performed by these partner organizations.

The consortium is distributed over 6 countries; Austria, Denmark, Finland, Germany, The Netherlands, and Poland. The composition of the consortium has been guided by the geographic spread of birch pollen allergy showing a distinct hotspot in Central and North-Western Europe.

Project coordination

Links to: